EMA/CHMP statement on Call to pool research resources into large multi-centre, multi-arm clinical trials to generate sound evidence on COVID-19 treatments

Dear Industry Stakeholders,

The EMA’s Human Medicines Committee (CHMP) has published a statement urging the EU research community to prioritise large randomised controlled studies because they are most likely to generate the conclusive evidence needed to enable rapid development and approval of potential treatments of CIVID-19. The statement promotes a harmonised approach to data collection and a robust methodology for COVID-19 clinical trials across the EU to make best use of the available supply of investigational agents. It emphasises the need to include all EU countries in these trials.

Please see further details in the enclosed link.

Need more information ?

BECRO

PLACE MARCEL BROODTHAERS PLEIN, 8 BOX 5
B-1060 BRUSSELS / BELGIUM
PHONE: +32 (0)2 892 40 00
E-MAIL: INFO@BECRO.BE

© 2018 BECRO – ALL RIGHTS RESERVED

Octopix + WordPress = ♥ | Design by Simplexity